Previous 10 | Next 10 |
Amryt Pharma (NASDAQ:AMYT): Q3 GAAP EPS of -$0.07. Revenue of $56.52M (+14.6% Y/Y) Press Release "Given the continued strong performance of the Company’s commercial products, the board is today reaffirming revenue guidance for FY 2021 in the range of $220M - $225M which represents grow...
Six multi-billion dollar deals announced last week. VICI Properties acquires MGM Growth Properties for $17.2 billion. Veoneer receives a superior bid from Qualcomm. For further details see: Merger Arbitrage Mondays - Veoneer Receives A Superior Bid From Qualcomm
Amryt Pharma (AMYT) Q2 2021 Earnings Conference Call August 06, 2021, 08:30 AM ET Company Participants Dr. Joe Wiley - CEO Rory Nealon - CFO and COO Mark Sumeray - Chief Medical Officer Sheila Frame - President, Americas Conference Call Participants Brandon Folkes - Cantor Fitzgerald Michelle...
The following slide deck was published by Amryt Pharma in conjunction with their 2021 Q2 earnings call. For further details see: Amryt Pharma 2021 Q2 - Results - Earnings Call Presentation
Amryt Pharma (NASDAQ:AMYT): Q2 GAAP EPS of -$0.04. Revenue of $62.76M (+35.9% Y/Y) The company raised revenue guidance for FY 2021 to a range of $210M - $215M versus prior guidance of $205M - $210M . Oleogel-S10 NDA accepted by the FDA, Priority Review ...
19 new deals announced in the month of July. Thoma Bravo acquires Medallia. Aon and Willis Towers Watson terminated their business combination agreement. For further details see: Merger Arbitrage Mondays - Thoma Bravo Announces 2 Large Deals In A Single Month ...
Welbilt receives a second more lucrative offer from the Ali Group that is well above the current all-stock deal with Middleby. Regulatory agencies flex their muscles with China’s antitrust regulator blocking Tencent Holdings’ plan to merge Huya and DouYu. EU approves...
Over 70 multi-billion dollar deals announced in the first half of the year. SPAC IPOs pick up pace and Chamath Palihapitiya files four new biotech focused SPACs. Icon completes the acquisition of PRA Health Sciences. For further details see: Merger Arbitrage Mondays - MK...
Publication of Circular to Amryt S hareholders in relation to the acquisition of Chiasma, Inc . , and p osting of Annual Report and Notice s of General Meeting s DUBLIN, Ireland, and Boston MA, 28 June 2021, Amryt (Nasdaq...
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc. DUBLIN, Ireland, and Boston MA, June 15, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company ...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...